Scaling MediTuner in New Markets Through Expanded Collaboration with AstraZeneca Global

Important results from the project

Yes, we have made key progress toward our goal. We have established contacts with AstraZeneca and U.S. clinics, launched clinical pilots in Vermont and Texas to evaluate clinical benefit and reimbursement, and deepened our understanding of business models, regulatory requirements, and the market. This lays the foundation for a future launch of MediTuner in the U.S.

Expected long term effects

Our U.S. initiative is expected to yield long-term effects including strong international partnerships, clinically validated solutions with clear patient benefit, sustainable business models, and deeper understanding of regulatory and commercial challenges. Pilots and mentorship lay the groundwork for market entry, improved care quality, increased patient engagement, and a strengthened global reputation for Swedish medtech.

Approach and implementation

Within our Vinnova-funded project, we have spent the past year working in three areas to prepare for a U.S. launch. We established strategic relationships with U.S. clinics and initiated dialogue with AstraZeneca. Two clinical pilots in Vermont and Texas are underway to evaluate clinical benefit and reimbursement opportunities. Through mentorship and the Tech Nordic Advocates program, we have deepened our understanding of business models, regulatory requirements, and the U.S. healthcare market.